Early depth of tumor shrinkage and treatment outcomes in non-small cell lung cancer treated using Nivolumab View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-04-01

AUTHORS

Hayato Kawachi, Daichi Fujimoto, Takeshi Morimoto, Kazutaka Hosoya, Yuki Sato, Mariko Kogo, Kazuma Nagata, Atsushi Nakagawa, Ryo Tachikawa, Keisuke Tomii

ABSTRACT

Background It would be useful to have criteria for predicting long-term treatment responses to immune checkpoint inhibitors (ICIs). Maximum depth of response correlates with treatment outcomes among patients receiving programmed death protein 1 axis inhibitors for non-small cell lung cancer (NSCLC). We investigated associations between early depth of response and survival outcomes among patients receiving nivolumab for NSCLC. Methods Using records from prospective observational cohorts, we identified 83 previously treated advanced patients with NSCLC who received nivolumab during 2016–2017. Thirty-one patients who achieved disease control were analyzed. Tumor assessments followed the Response Evaluation Criteria in Solid Tumors (RECIST). Using Kaplan-Meier and receiver operating characteristic (ROC) curve analyses, treatment outcomes were compared with percent tumor reductions from baseline to the first evaluation (8–12 weeks after starting nivolumab). Results Early depth of response was predictive of 6-month progression-free survival (area under the ROC curve, 0.848). Based on ROC results, early tumor shrinkage was defined as a > 10% reduction by the first evaluation. Early tumor shrinkage was associated with significantly longer median progression-free survival (early tumor shrinkage: 16.6 months, 95% confidence interval [CI] 8.5 months–not reached; no early shrinkage: 5.1 months, 95% CI 3.9–6.8 months; P < 0.001) and significantly longer median overall survival (P = 0.046). Conclusions Early depth of tumor shrinkage was associated with outcomes after ICI treatment. Because of its simplicity and predictive ability, early tumor shrinkage may be a promising factor for use in clinical settings. However, confirmation of our results is needed. More... »

PAGES

1257-1265

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10637-019-00770-y

DOI

http://dx.doi.org/10.1007/s10637-019-00770-y

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1113177740

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30937690


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents, Immunological", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Non-Small-Cell Lung", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kaplan-Meier Estimate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lung Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Nivolumab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "ROC Curve", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Response Evaluation Criteria in Solid Tumors", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Respiratory Medicine, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-ku, 650-0047, Kobe, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410843.a", 
          "name": [
            "Department of Respiratory Medicine, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-ku, 650-0047, Kobe, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kawachi", 
        "givenName": "Hayato", 
        "id": "sg:person.011470522113.61", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011470522113.61"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Respiratory Medicine, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-ku, 650-0047, Kobe, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410843.a", 
          "name": [
            "Department of Respiratory Medicine, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-ku, 650-0047, Kobe, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fujimoto", 
        "givenName": "Daichi", 
        "id": "sg:person.0752614316.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752614316.52"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Clinical Epidemiology, Hyogo College of Medicine, 1-1 Mukogawa-cho, 663-8131, Nishinomiya, Japan", 
          "id": "http://www.grid.ac/institutes/grid.272264.7", 
          "name": [
            "Clinical Research Center, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-ku, 650-0047, Kobe, Japan", 
            "Department of Clinical Epidemiology, Hyogo College of Medicine, 1-1 Mukogawa-cho, 663-8131, Nishinomiya, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Morimoto", 
        "givenName": "Takeshi", 
        "id": "sg:person.011273662612.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011273662612.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Respiratory Medicine, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-ku, 650-0047, Kobe, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410843.a", 
          "name": [
            "Department of Respiratory Medicine, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-ku, 650-0047, Kobe, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hosoya", 
        "givenName": "Kazutaka", 
        "id": "sg:person.016016734267.92", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016016734267.92"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Respiratory Medicine, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-ku, 650-0047, Kobe, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410843.a", 
          "name": [
            "Department of Respiratory Medicine, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-ku, 650-0047, Kobe, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sato", 
        "givenName": "Yuki", 
        "id": "sg:person.01044701724.61", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01044701724.61"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Respiratory Medicine, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-ku, 650-0047, Kobe, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410843.a", 
          "name": [
            "Department of Respiratory Medicine, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-ku, 650-0047, Kobe, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kogo", 
        "givenName": "Mariko", 
        "id": "sg:person.0624576212.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0624576212.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Respiratory Medicine, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-ku, 650-0047, Kobe, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410843.a", 
          "name": [
            "Department of Respiratory Medicine, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-ku, 650-0047, Kobe, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nagata", 
        "givenName": "Kazuma", 
        "id": "sg:person.01300361475.63", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01300361475.63"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Respiratory Medicine, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-ku, 650-0047, Kobe, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410843.a", 
          "name": [
            "Department of Respiratory Medicine, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-ku, 650-0047, Kobe, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nakagawa", 
        "givenName": "Atsushi", 
        "id": "sg:person.011042354025.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011042354025.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Respiratory Medicine, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-ku, 650-0047, Kobe, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410843.a", 
          "name": [
            "Department of Respiratory Medicine, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-ku, 650-0047, Kobe, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tachikawa", 
        "givenName": "Ryo", 
        "id": "sg:person.0655423507.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0655423507.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Respiratory Medicine, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-ku, 650-0047, Kobe, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410843.a", 
          "name": [
            "Department of Respiratory Medicine, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-ku, 650-0047, Kobe, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tomii", 
        "givenName": "Keisuke", 
        "id": "sg:person.01340443712.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340443712.07"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2019-04-01", 
    "datePublishedReg": "2019-04-01", 
    "description": "Background It would be useful to have criteria for predicting long-term treatment responses to immune checkpoint inhibitors (ICIs). Maximum depth of response correlates with treatment outcomes among patients receiving programmed death protein 1 axis inhibitors for non-small cell lung cancer (NSCLC). We investigated associations between early depth of response and survival outcomes among patients receiving nivolumab for NSCLC. Methods Using records from prospective observational cohorts, we identified 83 previously treated advanced patients with NSCLC who received nivolumab during 2016\u20132017. Thirty-one patients who achieved disease control were analyzed. Tumor assessments followed the Response Evaluation Criteria in Solid Tumors (RECIST). Using Kaplan-Meier and receiver operating characteristic (ROC) curve analyses, treatment outcomes were compared with percent tumor reductions from baseline to the first evaluation (8\u201312\u00a0weeks after starting nivolumab). Results Early depth of response was predictive of 6-month progression-free survival (area under the ROC curve, 0.848). Based on ROC results, early tumor shrinkage was defined as a\u2009>\u200910% reduction by the first evaluation. Early tumor shrinkage was associated with significantly longer median progression-free survival (early tumor shrinkage: 16.6\u00a0months, 95% confidence interval [CI] 8.5\u00a0months\u2013not reached; no early shrinkage: 5.1\u00a0months, 95% CI 3.9\u20136.8\u00a0months; P\u2009<\u20090.001) and significantly longer median overall survival (P\u2009=\u20090.046). Conclusions Early depth of tumor shrinkage was associated with outcomes after ICI treatment. Because of its simplicity and predictive ability, early tumor shrinkage may be a promising factor for use in clinical settings. However, confirmation of our results is needed.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s10637-019-00770-y", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094201", 
        "issn": [
          "0167-6997", 
          "1573-0646"
        ], 
        "name": "Investigational New Drugs", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "37"
      }
    ], 
    "keywords": [
      "non-small cell lung cancer", 
      "early tumor shrinkage", 
      "immune checkpoint inhibitors", 
      "progression-free survival", 
      "cell lung cancer", 
      "tumor shrinkage", 
      "treatment outcomes", 
      "lung cancer", 
      "longer median progression-free survival", 
      "median progression-free survival", 
      "longer median overall survival", 
      "long-term treatment response", 
      "prospective observational cohort", 
      "median overall survival", 
      "Response Evaluation Criteria", 
      "characteristic curve analysis", 
      "checkpoint inhibitors", 
      "ICI treatment", 
      "observational cohort", 
      "advanced patients", 
      "overall survival", 
      "survival outcomes", 
      "Kaplan-Meier", 
      "tumor reduction", 
      "treatment response", 
      "tumor assessment", 
      "solid tumors", 
      "earlier depth", 
      "patients", 
      "first evaluation", 
      "nivolumab", 
      "response correlates", 
      "clinical setting", 
      "disease control", 
      "curve analysis", 
      "outcomes", 
      "survival", 
      "ROC results", 
      "cancer", 
      "promising factor", 
      "inhibitors", 
      "response", 
      "cohort", 
      "tumors", 
      "predictive ability", 
      "baseline", 
      "treatment", 
      "criteria", 
      "evaluation", 
      "association", 
      "correlates", 
      "reduction", 
      "evaluation criteria", 
      "confirmation", 
      "setting", 
      "assessment", 
      "factors", 
      "records", 
      "control", 
      "background", 
      "shrinkage", 
      "results", 
      "use", 
      "ability", 
      "receiver", 
      "analysis", 
      "method", 
      "depth", 
      "maximum depth", 
      "simplicity"
    ], 
    "name": "Early depth of tumor shrinkage and treatment outcomes in non-small cell lung cancer treated using Nivolumab", 
    "pagination": "1257-1265", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1113177740"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10637-019-00770-y"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30937690"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10637-019-00770-y", 
      "https://app.dimensions.ai/details/publication/pub.1113177740"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:45", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_806.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s10637-019-00770-y"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10637-019-00770-y'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10637-019-00770-y'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10637-019-00770-y'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10637-019-00770-y'


 

This table displays all metadata directly associated to this object as RDF triples.

254 TRIPLES      20 PREDICATES      109 URIs      101 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10637-019-00770-y schema:about N1960d027262249e7b006b036f556c1f4
2 N1de8aa9d26a34d4daa792a0892d145a2
3 N1e63df1dc272455b927faa6bcc8edbba
4 N2ba0b34fab194a458396874f0dce24a8
5 N517c2760d10f42f194ba04af2187c358
6 N68a8f5d393f64efcab8886ed95e444da
7 N7d81954be7c446638490ffc926b5d623
8 N81864a0976094eb08ea01b996e00b42b
9 Na3a858f52bef4b839ddcb3ca2a1a7949
10 Nc09ca52900b745caa8de7f25b45860ed
11 Nd3746c2031fb462181a9f527aa769f7d
12 Nd84b508ace004469a27c372116e6668f
13 Nf132f3cfc0f848db8af0b2b54ca5925c
14 Nf6eb6a13b3224cebacc1f72e0f94870a
15 anzsrc-for:11
16 anzsrc-for:1112
17 schema:author N760a29a926d642dd91079aea7d6cd3a8
18 schema:datePublished 2019-04-01
19 schema:datePublishedReg 2019-04-01
20 schema:description Background It would be useful to have criteria for predicting long-term treatment responses to immune checkpoint inhibitors (ICIs). Maximum depth of response correlates with treatment outcomes among patients receiving programmed death protein 1 axis inhibitors for non-small cell lung cancer (NSCLC). We investigated associations between early depth of response and survival outcomes among patients receiving nivolumab for NSCLC. Methods Using records from prospective observational cohorts, we identified 83 previously treated advanced patients with NSCLC who received nivolumab during 2016–2017. Thirty-one patients who achieved disease control were analyzed. Tumor assessments followed the Response Evaluation Criteria in Solid Tumors (RECIST). Using Kaplan-Meier and receiver operating characteristic (ROC) curve analyses, treatment outcomes were compared with percent tumor reductions from baseline to the first evaluation (8–12 weeks after starting nivolumab). Results Early depth of response was predictive of 6-month progression-free survival (area under the ROC curve, 0.848). Based on ROC results, early tumor shrinkage was defined as a > 10% reduction by the first evaluation. Early tumor shrinkage was associated with significantly longer median progression-free survival (early tumor shrinkage: 16.6 months, 95% confidence interval [CI] 8.5 months–not reached; no early shrinkage: 5.1 months, 95% CI 3.9–6.8 months; P < 0.001) and significantly longer median overall survival (P = 0.046). Conclusions Early depth of tumor shrinkage was associated with outcomes after ICI treatment. Because of its simplicity and predictive ability, early tumor shrinkage may be a promising factor for use in clinical settings. However, confirmation of our results is needed.
21 schema:genre article
22 schema:isAccessibleForFree false
23 schema:isPartOf N28596bb5ed474d689275534ed21ed973
24 N3f53e045d34f4d00aa3c4a6eda5341ff
25 sg:journal.1094201
26 schema:keywords ICI treatment
27 Kaplan-Meier
28 ROC results
29 Response Evaluation Criteria
30 ability
31 advanced patients
32 analysis
33 assessment
34 association
35 background
36 baseline
37 cancer
38 cell lung cancer
39 characteristic curve analysis
40 checkpoint inhibitors
41 clinical setting
42 cohort
43 confirmation
44 control
45 correlates
46 criteria
47 curve analysis
48 depth
49 disease control
50 earlier depth
51 early tumor shrinkage
52 evaluation
53 evaluation criteria
54 factors
55 first evaluation
56 immune checkpoint inhibitors
57 inhibitors
58 long-term treatment response
59 longer median overall survival
60 longer median progression-free survival
61 lung cancer
62 maximum depth
63 median overall survival
64 median progression-free survival
65 method
66 nivolumab
67 non-small cell lung cancer
68 observational cohort
69 outcomes
70 overall survival
71 patients
72 predictive ability
73 progression-free survival
74 promising factor
75 prospective observational cohort
76 receiver
77 records
78 reduction
79 response
80 response correlates
81 results
82 setting
83 shrinkage
84 simplicity
85 solid tumors
86 survival
87 survival outcomes
88 treatment
89 treatment outcomes
90 treatment response
91 tumor assessment
92 tumor reduction
93 tumor shrinkage
94 tumors
95 use
96 schema:name Early depth of tumor shrinkage and treatment outcomes in non-small cell lung cancer treated using Nivolumab
97 schema:pagination 1257-1265
98 schema:productId N49985099b68c42fabae18574808439b0
99 N7096e48770984ea49902dfae05dc5f77
100 Ne79854d8d4a14008b055bdd906e55003
101 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113177740
102 https://doi.org/10.1007/s10637-019-00770-y
103 schema:sdDatePublished 2022-10-01T06:45
104 schema:sdLicense https://scigraph.springernature.com/explorer/license/
105 schema:sdPublisher N4ade8a911a1a4dd2b62983485279543c
106 schema:url https://doi.org/10.1007/s10637-019-00770-y
107 sgo:license sg:explorer/license/
108 sgo:sdDataset articles
109 rdf:type schema:ScholarlyArticle
110 N1960d027262249e7b006b036f556c1f4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Adult
112 rdf:type schema:DefinedTerm
113 N1de8aa9d26a34d4daa792a0892d145a2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Lung Neoplasms
115 rdf:type schema:DefinedTerm
116 N1e63df1dc272455b927faa6bcc8edbba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Carcinoma, Non-Small-Cell Lung
118 rdf:type schema:DefinedTerm
119 N28596bb5ed474d689275534ed21ed973 schema:issueNumber 6
120 rdf:type schema:PublicationIssue
121 N2ba0b34fab194a458396874f0dce24a8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Kaplan-Meier Estimate
123 rdf:type schema:DefinedTerm
124 N3c8596c6ef5145d6b8869c15744c74b3 rdf:first sg:person.0655423507.20
125 rdf:rest Nbce6e8de985b40459836cbfa8a7f42b0
126 N3f53e045d34f4d00aa3c4a6eda5341ff schema:volumeNumber 37
127 rdf:type schema:PublicationVolume
128 N4059a99c68384cbf9d66d8f438d8c95e rdf:first sg:person.016016734267.92
129 rdf:rest Nfd4ff22bb28a4decb3a97e0243975195
130 N49985099b68c42fabae18574808439b0 schema:name pubmed_id
131 schema:value 30937690
132 rdf:type schema:PropertyValue
133 N4ade8a911a1a4dd2b62983485279543c schema:name Springer Nature - SN SciGraph project
134 rdf:type schema:Organization
135 N517c2760d10f42f194ba04af2187c358 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Nivolumab
137 rdf:type schema:DefinedTerm
138 N68a8f5d393f64efcab8886ed95e444da schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Humans
140 rdf:type schema:DefinedTerm
141 N7096e48770984ea49902dfae05dc5f77 schema:name dimensions_id
142 schema:value pub.1113177740
143 rdf:type schema:PropertyValue
144 N760a29a926d642dd91079aea7d6cd3a8 rdf:first sg:person.011470522113.61
145 rdf:rest Nf99d5c4dd7204c6cbdf7f3f619d38581
146 N7d81954be7c446638490ffc926b5d623 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name ROC Curve
148 rdf:type schema:DefinedTerm
149 N81864a0976094eb08ea01b996e00b42b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Aged
151 rdf:type schema:DefinedTerm
152 N8b0cc4863eeb4fd9ad65cdc6f4560079 rdf:first sg:person.01300361475.63
153 rdf:rest Ne1d303b05b7c4b628ef8bc488993b872
154 Na3a858f52bef4b839ddcb3ca2a1a7949 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Female
156 rdf:type schema:DefinedTerm
157 Nb4dc01b6a1b7456a886f8970116af2bf rdf:first sg:person.011273662612.03
158 rdf:rest N4059a99c68384cbf9d66d8f438d8c95e
159 Nbce6e8de985b40459836cbfa8a7f42b0 rdf:first sg:person.01340443712.07
160 rdf:rest rdf:nil
161 Nc09ca52900b745caa8de7f25b45860ed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Middle Aged
163 rdf:type schema:DefinedTerm
164 Nd2862d3b8f1146c2908f9130f0036ab3 rdf:first sg:person.0624576212.46
165 rdf:rest N8b0cc4863eeb4fd9ad65cdc6f4560079
166 Nd3746c2031fb462181a9f527aa769f7d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Response Evaluation Criteria in Solid Tumors
168 rdf:type schema:DefinedTerm
169 Nd84b508ace004469a27c372116e6668f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Male
171 rdf:type schema:DefinedTerm
172 Ne1d303b05b7c4b628ef8bc488993b872 rdf:first sg:person.011042354025.34
173 rdf:rest N3c8596c6ef5145d6b8869c15744c74b3
174 Ne79854d8d4a14008b055bdd906e55003 schema:name doi
175 schema:value 10.1007/s10637-019-00770-y
176 rdf:type schema:PropertyValue
177 Nf132f3cfc0f848db8af0b2b54ca5925c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Aged, 80 and over
179 rdf:type schema:DefinedTerm
180 Nf6eb6a13b3224cebacc1f72e0f94870a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Antineoplastic Agents, Immunological
182 rdf:type schema:DefinedTerm
183 Nf99d5c4dd7204c6cbdf7f3f619d38581 rdf:first sg:person.0752614316.52
184 rdf:rest Nb4dc01b6a1b7456a886f8970116af2bf
185 Nfd4ff22bb28a4decb3a97e0243975195 rdf:first sg:person.01044701724.61
186 rdf:rest Nd2862d3b8f1146c2908f9130f0036ab3
187 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
188 schema:name Medical and Health Sciences
189 rdf:type schema:DefinedTerm
190 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
191 schema:name Oncology and Carcinogenesis
192 rdf:type schema:DefinedTerm
193 sg:journal.1094201 schema:issn 0167-6997
194 1573-0646
195 schema:name Investigational New Drugs
196 schema:publisher Springer Nature
197 rdf:type schema:Periodical
198 sg:person.01044701724.61 schema:affiliation grid-institutes:grid.410843.a
199 schema:familyName Sato
200 schema:givenName Yuki
201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01044701724.61
202 rdf:type schema:Person
203 sg:person.011042354025.34 schema:affiliation grid-institutes:grid.410843.a
204 schema:familyName Nakagawa
205 schema:givenName Atsushi
206 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011042354025.34
207 rdf:type schema:Person
208 sg:person.011273662612.03 schema:affiliation grid-institutes:grid.272264.7
209 schema:familyName Morimoto
210 schema:givenName Takeshi
211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011273662612.03
212 rdf:type schema:Person
213 sg:person.011470522113.61 schema:affiliation grid-institutes:grid.410843.a
214 schema:familyName Kawachi
215 schema:givenName Hayato
216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011470522113.61
217 rdf:type schema:Person
218 sg:person.01300361475.63 schema:affiliation grid-institutes:grid.410843.a
219 schema:familyName Nagata
220 schema:givenName Kazuma
221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01300361475.63
222 rdf:type schema:Person
223 sg:person.01340443712.07 schema:affiliation grid-institutes:grid.410843.a
224 schema:familyName Tomii
225 schema:givenName Keisuke
226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340443712.07
227 rdf:type schema:Person
228 sg:person.016016734267.92 schema:affiliation grid-institutes:grid.410843.a
229 schema:familyName Hosoya
230 schema:givenName Kazutaka
231 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016016734267.92
232 rdf:type schema:Person
233 sg:person.0624576212.46 schema:affiliation grid-institutes:grid.410843.a
234 schema:familyName Kogo
235 schema:givenName Mariko
236 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0624576212.46
237 rdf:type schema:Person
238 sg:person.0655423507.20 schema:affiliation grid-institutes:grid.410843.a
239 schema:familyName Tachikawa
240 schema:givenName Ryo
241 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0655423507.20
242 rdf:type schema:Person
243 sg:person.0752614316.52 schema:affiliation grid-institutes:grid.410843.a
244 schema:familyName Fujimoto
245 schema:givenName Daichi
246 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752614316.52
247 rdf:type schema:Person
248 grid-institutes:grid.272264.7 schema:alternateName Department of Clinical Epidemiology, Hyogo College of Medicine, 1-1 Mukogawa-cho, 663-8131, Nishinomiya, Japan
249 schema:name Clinical Research Center, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-ku, 650-0047, Kobe, Japan
250 Department of Clinical Epidemiology, Hyogo College of Medicine, 1-1 Mukogawa-cho, 663-8131, Nishinomiya, Japan
251 rdf:type schema:Organization
252 grid-institutes:grid.410843.a schema:alternateName Department of Respiratory Medicine, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-ku, 650-0047, Kobe, Japan
253 schema:name Department of Respiratory Medicine, Kobe City Medical Center General Hospital, 2-1-1 Minatojima-Minamimachi, Chuo-ku, 650-0047, Kobe, Japan
254 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...